Status:

UNKNOWN

PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)

Lead Sponsor:

University of Toyama

Collaborating Sponsors:

Seoul National University Hospital

Kansai Medical University

Conditions:

Disease of Pancreatic or Periampullary Lesions

Eligibility:

All Genders

20+ years

Phase:

PHASE3

Brief Summary

The polyglycolic acid (PGA) felt is a felt-like absorbable suture reinforcing material. The pancreatojejunostomy aimed at reducing POPF is not established at present. We devised a new method using dou...

Detailed Description

Pancreatojejunostomy is generally a combination of suture between the pancreatic parenchyma and the seromuscular layer of the jejunum, and duct-to-mucosa suture. The clinical study about the various k...

Eligibility Criteria

Inclusion

  • Disease of pancreatic or periampullary lesions to require pancreatoduodenectomy
  • Planned pancreaticojejunostomy including duct-to-mucosa anastomosis
  • MPD diameter ≤3mm on the left side of the portal vein in preoperative imaging (CT or MRI)
  • Performance status (ECOG scale): 0-1 at the time of enrollment
  • Age: 20 years or older
  • Adequate organ function A) Leukocyte count: ≥2500 mm3, ≤14000 mm3 B) Hemoglobin: ≥9.0 g/dL C) Platelet count: ≥100,000 mm3 D) Total Bilirubin: ≤2.0 mg/dL (not apply to cases with obstructive jaundice) E) Creatinine: ≤2.0 mg/dL
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion

  • Planned pancreatogastrostomy
  • Laparoscopic or laparoscope-assisted pancreatoduodenectomy
  • Pancreatic parenchymal atrophy or calcification due to chronic pancreatitis
  • Neoadjuvant treatment including chemotherapy or radiotherapy
  • History of upper abdominal surgery (both of open and laparoscopic) except cholecystectomy
  • Emergency operation
  • Arterial reconstruction such as superior mesenteric artery, common hepatic artery, or celiac artery
  • Severe ischemic heart disease
  • Severe liver dysfunction due to liver cirrhosis or active hepatitis
  • Severe respiratory disorder required oxygen inhalation
  • Chronic renal failure with dialysis
  • Requiring resection of other organs (liver or colon) during pancreatoduodenectomy
  • Immunosuppressive treatment
  • History of severe hypersensitivity to PGA felt and fibrin glue
  • Other severe drug allergies
  • Contrast media allergy of both iodine and gadolinium
  • Active duplicate cancer thought to affect adverse events
  • Severe psychological or neurological disease
  • Drug abuse or alcoholics
  • Planned use of octreotide

Key Trial Info

Start Date :

October 10 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

514 Patients enrolled

Trial Details

Trial ID

NCT03331718

Start Date

October 10 2018

End Date

December 31 2024

Last Update

May 10 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Toyama

Toyama, Japan, 9300194